Clinical Trial Detail

NCT ID NCT02792725
Title Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib

Age Groups: adult senior

Additional content available in CKB BOOST